Candel Therapeutics Raises $100M in Public Offering to Advance Cancer Immunotherapy Pipeline
Event summary
- Candel Therapeutics priced a public offering of 18,348,624 shares at $5.45 per share, raising $100M before expenses.
- Proceeds will fund launch readiness and commercial activities for aglatimagene besadenovec in early prostate cancer and phase 3 trial costs for NSCLC.
- Underwriters have a 30-day option to purchase up to 2,752,293 additional shares.
- The offering is expected to close on or about February 23, 2026.
The big picture
Candel Therapeutics' $100M public offering underscores the capital-intensive nature of advancing cancer immunotherapies through late-stage clinical trials. The funding will support critical commercialization efforts for aglatimagene besadenovec, a product with multiple FDA designations, including Fast Track and Regenerative Medicine Advanced Therapy. The move comes as biotech firms increasingly rely on public markets to finance costly oncology pipelines, reflecting broader industry trends toward specialized, multimodal treatments.
What we're watching
- Clinical Milestones
- The pace at which aglatimagene besadenovec advances through regulatory approvals for prostate cancer and NSCLC will determine commercial viability.
- Market Dynamics
- Whether Candel can sustain investor interest amid competitive pressures in the cancer immunotherapy space.
- Execution Risk
- How effectively Candel deploys the $100M raised to meet launch readiness and phase 3 trial objectives.
Related topics